Chicago,

"Remember that the Royalty Preferred Shares are in addition to the above. There are ~ 75,000,000 Royalty Preferred Shares Outstanding. I would think that  the price per share would be further diluted by the revenue stream allocated to these shares. Thinking in terms of 8bil as a benchmark for a BTD, a portion of those dollars may go to Zenith Royalty Preferred Shares. $20US/sh? after stripping off the RPS liability."

Any idea what sort of revenue a Big Pharma needs to generate annually with Apabetalone (etc.) for the patent's life to pay out $8bil US?

-Would the RVX-RPS be treated the same way as RVX-common shares when it comes to dividing up the $8bil US proceeds? Or do they only pay out a 6-12% dividend on net APO revenue is any? In a total sellout of RVX, revenue would be zero. 

Koo